Skip to main content

Table 1 Anagraphical and clinical information characteristics of the enrolled patients

From: Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders

Characteristics N (%) aGvHD No aGvHD P
Age (years) ns
Mean 8.4   8.2 9.0  
Range 1–21   2–19 1–21  
Female Sex 12 33.3 6 6  
Disease ns
 ALL 14 38.9 7 7  
 AML 9 25.0 4 5  
 Thalassemia Major 5 13.9 2 3  
 SAA 3 8.3 2 1  
 BDA 3 8.3 2 1  
 CDA 1 2.8 1 0  
 ALPS 1 2.8 1 0  
Riska ns
 High Risk 8 22.2 5 3  
 Standard Risk 28 77.8 14 14  
Graft Source ns
 Unmodified BM 29 80.6 16 13  
 T-cell Depleted PBSC 6 16.7 2 4  
 Cord Blood 1 2.8 1 0  
Matching HLA ns
 Matched 26 72.2 14 12  
 Mismatched 10 27.8 5 5  
Conditioning Regimenb ns
 Myeloablative 35 88.9 18 16  
 Nonmyeloablative 1 11.1 1 0  
GvHD Prophylaxis ns
 αβ T-cell and B-cell depletion 6 16.7 3 3  
 Calcineurin Inhibitor alone 7 19.4 4 3  
 CI + ATG +/− MTX 21 58.3 11 10  
 CI + ATG + Prednisone 1 2.8 1 0  
 CI + Cyclophosphamide post 1 2.8 0 1  
GvHD 19 52.8    
 Mean Day of Onset (days from transplantation) + 21     
 I 5 26.3    
 II 9 47.4    
 III 3 15.8    
 IV 2 10.5    
 Gut Involvement 6 31.6    
  1. Abbreviations: ALL Acute Lymphoblastic Leukemia, AML Acute Myeloid Leukemia, SAA Severe Aplastic Anemia, BDA Blackfan-Diamond Anemia, CDA Congenital Dyserythropoietic Anemia, ALPS Autoimmune Lymphoproliferative Syndrome, BM Bone Marrow, PBSC Peripheral Blood Stem Cells, GvHD Graft-versus-Host Disease, ATG Anti-Thymocyte Globulin, MTX Methotrexate, ns not significant
  2. aRisk staging: high risk: >1st complete remission (CR) or refractory disease; standard risk: 1st CR or non-malignant disease
  3. bAs defined by Bacigalupo et al. [50]